Actelion chronicles

Actelion's stock price rose from November 2001, when its Tracleer bosentan oral endothelin receptor antagonist was approved in the U.S. for pulmonary arterial hypertension, driven by sales that took the company to profitability.The shares peaked Feb. 17, 2004, as late-stage newsflow started coming out on competing endothelin receptor antagonists Thelin sitaxsentan from Encysive (ENCY) and ambrisentan from Myogen (MYOG). ATLN also had clinical setbacks, including halting Phase III trials of Veletri tezosentan for acute heart failure (AHF) and discontinuing development of palosuran, a Phase II diabetic nephropathy compound. Selected events tracked against ATLN's weekly stock price since mid-2001.

A. 11/20/01 - FDA approves Tracleer for PAH ...